PremiumRatingsPromising Oncology Developments and Strong Financial Outlook Support Buy Rating for Vir Biotechnology Vir Biotechnology: Balancing Long-term Potential with Near-term Uncertainty – A Hold Rating Analysis Vir Biotechnology’s Promising Pipeline and Strong Financial Position Justify Buy Rating PremiumCompany AnnouncementsVir Biotechnology Announces Leadership Change in 2025 Biotech Alert: Searches spiking for these stocks today Largest borrow rate increases among liquid names PremiumThe FlyVir Biotechnology presents safety, efficacy data in VIR-5818 and VIR-5500 trials Vir Biotechnology price target lowered to $14 from $15 at BofA FDA revokes EUAs for some antibody treatments for COVID-19 
